A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors

Annals of Oncology

Volumn 27, Issue 3, 2016, Pages 526-532

  Tolcher, Anthony W ^a   Papadopoulos, K P ^a   Patnaik, A ^a   Wilson, K ^b   Thayer, S ^c   Zanghi, J ^c   Gemo, A T ^c   Kavanaugh, W M ^c   Keer, H N ^c   LoRusso, P M ^b,d  

^a South Texas Accelerated Research Therapeutics (START)   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c FIVE PRIME THERAPEUTICS INC   (United States)

^d YALE CANCER CENTER   (United States)

Author keywords

Cancer; FGF; Ligand trap; Phase I

Indexed keywords

CETUXIMAB; DOCETAXEL; FIBROBLAST GROWTH FACTOR 2; FLUORODEOXYGLUCOSE; FP 1039; MAGNESIUM; PANITUMUMAB; PHOSPHATE; RECOMBINANT FIBROBLAST GROWTH FACTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; FGFR1 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FP-1039; IMMUNOGLOBULIN G; ONCOPROTEIN;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER SCREENING; CLINICAL ARTICLE; COLON CANCER; CYTOLOGY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; FGR1 GENE; FOLLOW UP; GENE AMPLIFICATION; HEAD AND NECK CANCER; HEADACHE; HEPATOBILIARY CANCER; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERGLYCEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; IMMUNOGENICITY; INOPERABLE CANCER; INTESTINE PERFORATION; LEUKOPENIA; MAGNESIUM BLOOD LEVEL; MALE; MAXIMUM PLASMA CONCENTRATION; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NAUSEA; NAUSEA AND VOMITING; NEUROENDOCRINE TUMOR; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OPEN STUDY; PANCREAS ADENOCARCINOMA; PERIPHERAL EDEMA; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PHOSPHATE BLOOD LEVEL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PRURITUS; RASH; RECTUM CANCER; SARCOMA; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SMALL BOWEL CANCER; SOFT TISSUE SARCOMA; SOLID TUMOR; TREATMENT DURATION; TREATMENT WITHDRAWAL; URTICARIA; UTERINE CERVIX CANCER; UTERUS CANCER; VOMITING; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CLINICAL TRIAL; DRUG EFFECTS; MAXIMUM TOLERATED DOSE; METABOLISM; MIDDLE AGED; NEOPLASMS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; IMMUNOGLOBULIN G; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; ONCOGENE PROTEINS, FUSION; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1;

EID: 84959935277     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv591     Document Type: Article

References (30)

1. Itoh N. The Fgf families in humans, mice, and zebrafish: their evolutional processes and roles in development, metabolism, and disease. Biol Pharm Bull 2007; 30: 1819-1825.
2. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009; 8: 235-253.
3. Long YC, Kharitonenkov A. Hormone-like fibroblast growth factors and metabolic regulation. Biochim Biophys Acta 2011; 1812: 791-795.
4. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010; 10: 116-129.
5. Weiss J, Sos ML, Seidel D et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010; 2: 62ra93.
6. Dutt A, Ramos AH, Hammerman PS et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One 2011; 6: e20351.
7. Turner NC, Seckl MJ. A therapeutic target for smoking-associated lung cancer. Sci Transl Med 2010; 2: 62ps56.
8. Gelsi-Boyer V, Orsetti B, Cervera N et al. Comprehensive profiling of 8p11-12 amplification in breast cancer. Mol Cancer Res 2005; 3: 655-667.
9. Chang J, Liu X, Wang S et al. Prognostic value of FGFR gene amplification in patients with different types of cancer: a systematic review and meta-analysis. PLoS ONE 2014; 9: e105524.
10. Nguyen M, Watanabe H, Budson AE et al. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 1994; 86: 356-361.
11. Sun HD, Malabunga M, Tonra JR et al. Monoclonal antibody antagonists of hypothalamic FGFR1 cause potent but reversible hypophagia and weight loss in rodents and monkeys. Am J Physiol Endocrinol Metab 2007; 292: E964-E976.
12. Guagnano V, Furet P, Spanka C et al. Discovery of 3-(2, 6-dichloro-3, 5-dimethoxyphenyl)-1-(6-[4-(4-ethyl-piperazin-1-yl)-phenylamin o]-pyrimidin-4-yl)-1-methylurea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J Med Chem 2011; 54: 7066-7083.
13. Paik PK, Shen R, Ferry D et al. A phase 1b open-label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers: preliminary antitumor activity and pharmacodynamic data. J Clin Oncol 2014; 32(suppl): abstr 8035.
14. Bahleda R, Dienstmann R, Adamo B et al. Phase 1 study of JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced solid tumors. J Clin Oncol 2014; 32(suppl): abstr 2501.
15. Nogova L, Lecia V, Sequist LV et al. Targeting FGFR1-amplified lung squamous cell carcinoma with the selective pan-FGFR inhibitor BGJ398. J Clin Oncol 2014; 32 (suppl): abstr 8034.
16. Harding TC, Long L, Palencia S et al. Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer. Sci Transl Med 2013; 5: 178ra39.
17. Kurosu H, Ogawa Y, Miyoshi M et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 2006; 281: 6120-6123.
18. Urakawa I, Yamazaki Y, Shimada T et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006; 444: 770-774.
19. De Young MP, Sherk C, Bleam M. et al. Preclinical efficacy of targeting FGF autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039/GSK3052230. In Proceedings of the 105th Annual Meeting of the American Association for Cancer Research, 5-9 April 2014; 2014. Abstract LB-236, p. 74. AACR, Cancer Res, San Diego, CA; Philadelphia, PA.
20. U.S. Department of Health and Human Services FaDA, Center for Drug Evaluation and Research (CDER) and Center for Veterinary Medicine (CVM). Guidance for Industry: Bioanalytical Method Validation. 2001.
21. Mire-Sluis AR, Barrett YC, Devanarayan V et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 2004; 289: 1-16.
22. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
23. Peifer M, Fernandez-Cuesta L, Sos ML et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 2012; 44: 1104-1110.
24. Kwek SS, Roy R, Zhou H et al. Co-amplified genes at 8p12 and 11q13 in breast tumors cooperate with two major pathways in oncogenesis. Oncogene 2009; 28: 1892-1903.
25. Freier K, Schwaenen C, Sticht C et al. Recurrent FGFR1 amplification and high FGFR1 protein expression in oral squamous cell carcinoma (OSCC). Oral Oncol 2007; 43: 60-66.
26. Brown AP, Courtney CL, King LM et al. Cartilage dysplasia and tissue mineralization in the rat following administration of a FGF receptor tyrosine kinase inhibitor. Toxicol Pathol 2005; 33: 449-455.
27. Emi M, Fujiwara Y, Nakajima T et al. Frequent loss of heterozygosity for loci on chromosome 8p in hepatocellular carcinoma, colorectal cancer, and lung cancer. Cancer Res 1992; 52: 5368-5372.
28. Knowles MA, Shaw ME, Proctor AJ. Deletion mapping of chromosome 8 in cancers of the urinary bladder using restriction fragment length polymorphisms and microsatellite polymorphisms. Oncogene 1993; 8: 1357-1364.
29. Harding TC, Palencia S, Wallace T et al. Preclinical efficacy of fibroblast growth factor ligand trap HGS1036 in lung carcinoma models with genomic amplification of FGFR1. In Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 31 March-4 April 2012; 2012. Abstract 1876, p. 72. AACR; Cancer Res, Chicago, IL; Philadelphia, PA.
30. Malchers F, Dietlein F, Schottle J et al. Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer. Cancer Discov 2014; 4: 246-257.